

Donald P Tashkin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5080289/donald-p-tashkin-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250
papers

15,252
citations

65
h-index

117
g-index

271
ext. papers

17,705
ext. citations

6.5
avg, IF

6.6
L-index

#	Paper	IF	Citations
250	The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 117-127	2.3	1
249	Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2021 , 31, 43	3.2	
248	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021 , 48, 1295-1298	4.1	4
247	The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. <i>Pulmonary Medicine</i> , 2021 , 2021, 8881895	5.3	2
246	Smoking cessation in COPD: confronting the challenge. <i>Internal and Emergency Medicine</i> , 2021 , 16, 545-547	5.7	3
245	Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>International Journal of COPD</i> , 2021 , 16, 945-955	3	1
244	Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. <i>Respiratory Research</i> , 2021 , 22, 142	7.3	5
243	Mid-expiratory time as a potential spirometric index of early airflow obstruction. <i>Respiratory Medicine</i> , 2021 , 176, 105977	4.6	
242	Long-term safety and efficacy studies of epinephrine HFA metered-dose inhaler (Primatene Mist): a two-stage randomized controlled trial. <i>Journal of Asthma</i> , 2021 , 58, 633-644	1.9	
241	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1005-1013	9.5	5
240	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , 2021 , 3, 8-16	3.5	1
239	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	1
238	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. <i>ACR Open Rheumatology</i> , 2020 , 2, 362-370	3.5	9
237	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 963-967	5.3	2
236	Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy. <i>International Journal of COPD</i> , 2020 , 15, 1225-1243	3	11
235	A Dose-Ranging Study of Epinephrine Hydrofluoroalkane Metered-Dose Inhaler (Primatene MIST) in Subjects with Intermittent or Mild-to-Moderate Persistent Asthma. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020 , 33, 186-193	3.8	0
234	Impact of marijuana smoking on lung function in older persons. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	0

233	Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking. <i>American Journal of Cardiology</i> , 2020 , 125, 1725-1731	3	4
232	Nebulized Treatments and the Possible Risk of Coronavirus Transmission: Where Is the Evidence?. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020 , 7, 136-138	2.7	9
231	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 650-660	10.2	41
230	Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020 , 15, 3105-3122	3	0
229	The use of nebulized pharmacotherapies during the COVID-19 pandemic. <i>Therapeutic Advances in Respiratory Disease</i> , 2020 , 14, 1753466620954366	4.9	14
228	Marijuana use and pneumonia risk in a cohort of HIV-infected and HIV-uninfected men. <i>Annals of Epidemiology</i> , 2020 , 52, 64-70.e2	6.4	1
227	Dietary glycemic index, glycemic load, and lung cancer risk: A case-control study in Los Angeles County. <i>Cancer Epidemiology</i> , 2020 , 69, 101824	2.8	1
226	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2020 , 72, 316-325	9.5	10
225	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 161-168	2.2	3
224	Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV/FVC. <i>Respiratory Medicine</i> , 2019 , 156, 58-68	4.6	20
223	Benefit:Risk Profile of Budesonide in Obstructive Airways Disease. <i>Drugs</i> , 2019 , 79, 1757-1775	12.1	12
222	Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study. <i>Chest</i> , 2019 , 155, 519-527	5.3	11
221	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019 , 21, 23	5.7	15
220	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2059-2067	9.5	29
219	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019 , 46, 1316-1325	4.1	18
218	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019 , 58, 567-579	3.9	35
217	Pulmonary effects of inhaled cannabis smoke. <i>American Journal of Drug and Alcohol Abuse</i> , 2019 , 45, 596-609	3.7	30
216	Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies. <i>Respiratory Medicine</i> , 2019 , 155, 113-120	4.6	4

215	Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. <i>Respiratory Research</i> , 2019 , 20, 135	7.3	6
214	Determining progression of scleroderma-related interstitial lung disease.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 62-70	2.3	7
213	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 122-130	2.4	88
212	Controversies in Allergy: Is Asthma Chronic Obstructive Pulmonary Disease Overlap a Distinct Syndrome That Changes Treatment and Patient Outcomes?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1142-1147	5.4	6
211	A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. <i>Journal of NeuroImmune Pharmacology</i> , 2018 , 13, 219-229	6.9	2
210	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. <i>Thorax</i> , 2018 , 73, 414-421	7.3	60
209	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , 2018 , 70, 439-444	4.7	35
208	Marijuana and Lung Disease. <i>Chest</i> , 2018 , 154, 653-663	5.3	34
207	Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018 , 13, 1873-1888	3	9
206	Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018 , 13, 335-349	3	72
205	Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 644-652	10.2	47
204	Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018 , 5, 46-56	2.7	13
203	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. <i>Respiratory Research</i> , 2018 , 19, 223	7.3	11
202	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT trial. <i>Respiratory Research</i> , 2018 , 19, 196	7.3	12
201	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1286-1295	4.7	48
200	Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. <i>International Journal of COPD</i> , 2018 , 13, 2587-2601	3	40
199	Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out. <i>Annals of Allergy, Asthma and Immunology</i> , 2017 , 118, 241-245	3.2	12
198	Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers. <i>International Journal of Cancer</i> , 2017 , 140, 2040-2050	7.5	8

197	Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. <i>EBioMedicine</i> , 2017 , 19, 139-145	8.8	21
196	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 636-642	4.7	21
195	Effect of a single exacerbation on decline in lung function in COPD. <i>Respiratory Medicine</i> , 2017 , 128, 85-94	4.6	30
194	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1451-1460	9.5	67
193	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017 , 126, 105-115	4.6	58
192	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. <i>Chest</i> , 2017 , 151, 813-820	5.3	35
191	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, v27-v32	3.9	20
190	Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. <i>Respiratory Medicine</i> , 2017 , 132, 31-41	4.6	33
189	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 956-967	35.1	140
188	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 619-626	35.1	148
187	Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 72-83	2.3	22
186	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. <i>PLoS ONE</i> , 2017 , 12, e0184606	3.7	11
185	Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 2045-2056	4.7	44
184	Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. <i>Cancer Causes and Control</i> , 2016 , 27, 1293-1300	2.8	10
183	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. <i>Respiratory Medicine</i> , 2016 , 120, 91-100	4.6	3
182	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016 , 18, 305	5.7	42
181	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. <i>Respiratory Medicine</i> , 2016 , 117, 198-206	4.6	70
180	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT trial. <i>Respiratory Research</i> , 2016 , 17, 48	7.3	6

179	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 374-814	3.4	55
178	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1367-71	2.4	29
177	A review of nebulized drug delivery in COPD. <i>International Journal of COPD</i> , 2016 , 11, 2585-2596	3	55
176	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. <i>Thorax</i> , 2016 , 71, 411-420	7.3	10
175	Tiotropium Respimat [®] Add-on to at Least Ics Therapy Demonstrates Reduced Risk of Severe Asthma Exacerbation and Asthma Worsening in Symptomatic Asthma, Independent of IgE or Blood Eosinophil Levels. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, AB214	11.5	3
174	Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 1571-1579.e10	11.5	35
173	Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016 , 4, 705-12	5.4	7
172	Once-Daily Tiotropium Respimat [®] Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, AB213	11.5	3
171	Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. <i>American Journal of Cardiology</i> , 2016 , 117, 1747-54	3	14
170	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. <i>Respiratory Medicine</i> , 2016 , 110, 16-21	4.6	18
169	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 708-719	35.1	487
168	Serum Bilirubin and Disease Progression in Mild COPD. <i>Chest</i> , 2015 , 148, 169-175	5.3	24
167	Efficacy of an inhaled corticosteroid/long-acting β -agonist combination in symptomatic COPD patients in GOLD groups B and D. <i>European Respiratory Journal</i> , 2015 , 46, 255-8	13.6	
166	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27	10.2	137
165	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 879-905	13.6	107
164	Dual anti-inflammatory agents prevent COPD exacerbations. <i>Lancet, The</i> , 2015 , 385, 832-4	4.0	2
163	Advances in Prevention and Treatment of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 455-6	3.9	
162	The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1587-9	4.7	3

161	Smoking Cessation in Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 491-507	3.9	39
160	Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT [®] trial. <i>Respiratory Research</i> , 2015 , 16, 65	7.3	38
159	Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. <i>Rheumatology (Sunnyvale, Calif)</i> , 2015 , 5,		10
158	Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. <i>International Journal of COPD</i> , 2015 , 10, 239-59	3	27
157	The relationship between Helicobacter pylori seropositivity and COPD. <i>Thorax</i> , 2015 , 70, 923-9	7.3	16
156	Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1700-10	4.7	16
155	How beneficial is vaping cannabis to respiratory health compared to smoking?. <i>Addiction</i> , 2015 , 110, 1706-7	4.7	20
154	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015 , 24, 159-72	9.8	50
153	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 372	5.7	61
152	An epidemiologic review of marijuana and cancer: an update. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 15-31	4	70
151	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT [®] Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 122-130	2.7	5
150	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT [®] Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 236-251	2.7	3
149	Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. <i>Respiratory Research</i> , 2014 , 15, 102	7.3	8
148	Subacute bronchial toxicity induced by an electronic cigarette: take home message. <i>Thorax</i> , 2014 , 69, 588	7.3	3
147	Roflumilast : the new orally active, selective phosphodiesterase-4 inhibitor, for the treatment of COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 85-96	4	37
146	Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. <i>Lung Cancer</i> , 2014 , 85, 449-56	5.9	7
145	Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. <i>Respiratory Medicine</i> , 2014 , 108, 1355-62	4.6	4
144	One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. <i>Chest</i> , 2014 , 146, 1531-1542	5.3	20

143	Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. <i>Journal of Asthma</i> , 2014 , 51, 603-9	1.9	22
142	Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2013 , 14, 49	7.3	121
141	Future of fixed-dose longacting β -agonist and antimuscarinic combination therapy in COPD. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 6-7	35.1	4
140	Effects of marijuana smoking on the lung. <i>Annals of the American Thoracic Society</i> , 2013 , 10, 239-47	4.7	144
139	A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. <i>Respiratory Medicine</i> , 2013 , 107, 1912-22	4.6	3
138	Annual rates of change in pre- vs. post-bronchodilator FEV ₁ and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1904-11	4.6	15
137	Variations in FEV ₁ decline over time in chronic obstructive pulmonary disease and its implications. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 116-24	3	28
136	A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. <i>Chest</i> , 2013 , 143, 1590-1598	5.3	291
135	Tiotropium for the treatment of chronic obstructive pulmonary disease. <i>Clinical Practice (London, England)</i> , 2013 , 10, 141-155	3	2
134	β blockers associated with reduced all-cause mortality in COPD. <i>Evidence-Based Medicine</i> , 2012 , 17, 31-2		1
133	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012 , 13, 66	7.3	14
132	Comparison of the variability of the annual rates of change in FEV ₁ determined from serial measurements of the pre- versus post-bronchodilator FEV ₁ over 5 years in mild to moderate COPD: results of the lung health study. <i>Respiratory Research</i> , 2012 , 13, 70	7.3	7
131	Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. <i>International Journal of COPD</i> , 2012 , 7, 73-86	3	21
130	Treatment of Interstitial Lung Disease 2012 , 421-427		1
129	Exacerbation frequency and course of COPD. <i>International Journal of COPD</i> , 2012 , 7, 653-61	3	109
128	Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. <i>International Journal of COPD</i> , 2012 , 7, 57-71	3	35
127	Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. <i>International Journal of COPD</i> , 2012 , 7, 43-55	3	10
126	Association of dopamine-related gene alleles, smoking behavior and decline in FEV ₁ in subjects with COPD: findings from the lung health study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 620-8	2	5

125	Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 367-74	2	30
124	Efficacy of tiotropium in COPD patients with FEV1 \geq 60% participating in the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 289-96	2	36
123	Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1301-6	10.2	70
122	Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. <i>Chest</i> , 2012 , 142, 614-621	5.3	35
121	Adverse events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011 , 124, 459-67	2.4	24
120	Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011 , 24, 147-52	3.5	20
119	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <i>Respiratory Medicine</i> , 2011 , 105, 1176-88	4.6	23
118	Premature discontinuation during the UPLIFT study. <i>Respiratory Medicine</i> , 2011 , 105, 1523-30	4.6	17
117	Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. <i>International Journal of COPD</i> , 2011 , 6, 269-75	3	4
116	What Justifies a Placebo-Controlled Trial of Varenicline for Smoking Cessation in Patients With COPD?: Response. <i>Chest</i> , 2011 , 139, 969-970	5.3	
115	Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. <i>Respirology</i> , 2011 , 16, 825-35	3.6	39
114	Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. <i>European Radiology</i> , 2011 , 21, 2455-65 ⁸		75
113	Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial. <i>Lung</i> , 2011 , 189, 261-8	2.9	46
112	Adverse health consequences in COPD patients with rapid decline in FEV1—evidence from the UPLIFT trial. <i>Respiratory Research</i> , 2011 , 12, 129	7.3	18
111	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , 2011 , 12, 6	7.3	57
110	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2797-808		83
109	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3078-85		85
108	Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. <i>Chest</i> , 2011 , 139, 591-599	5.3	151

107	Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. <i>International Journal of COPD</i> , 2010 , 5, 41-53	3	9
106	Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2010 , 4, 703-14	3.8	4
105	Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. <i>Expert Review of Respiratory Medicine</i> , 2010 , 4, 279-89	3.8	12
104	Cardiovascular safety of tiotropium in patients with COPD. <i>Chest</i> , 2010 , 137, 20-30	5.3	148
103	Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype?. <i>New England Journal of Medicine</i> , 2010 , 363, 1183-4	59.2	18
102	Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. <i>Respiratory Research</i> , 2010 , 11, 149	7.3	89
101	Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. <i>Respiratory Medicine</i> , 2010 , 104, 1495-504	4.6	58
100	Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2077-85	4	10
99	Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16, 97-105	3	40
98	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010 , 62, 1772-8	4.7	26
97	Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. <i>Journal of Rheumatology</i> , 2009 , 36, 773-80	4.1	118
96	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. <i>Chest</i> , 2009 , 136, 1333-1340	5.3	104
95	Does smoking marijuana increase the risk of chronic obstructive pulmonary disease?. <i>Cmaj</i> , 2009 , 180, 797-8	3.5	13
94	Minimally important differences in the Mahler [®] Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. <i>Rheumatology</i> , 2009 , 48, 1537-40	3.9	36
93	Defining disease modification in chronic obstructive pulmonary disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 211-25	2	24
92	Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 948-55	10.2	209
91	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. <i>Current Rheumatology Reports</i> , 2009 , 11, 111-9	4.9	40
90	Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. <i>Advances in Therapy</i> , 2009 , 26, 1024-34	4.1	7

89	Smoking cessation in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2009 , 103, 963-74	4.6	81
88	Imaging of the distal airways. <i>Journal of Allergy and Clinical Immunology</i> , 2009 , 124, S78-83	11.5	10
87	Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. <i>Drugs</i> , 2009 , 69, 549-65	12.1	156
86	Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 404-15	2	48
85	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. <i>Lancet, The</i> , 2009 , 374, 712-9	40	155
84	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 1171-8	40	365
83	Budesonide and risk of pneumonia [AuthorsPreply]. <i>Lancet, The</i> , 2009 , 374, 2051-2052	40	2
82	Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009 , 6, 17-25	2	118
81	Tiotropium HandiHaler in the treatment of COPD: a safety review. <i>International Journal of COPD</i> , 2009 , 4, 397-409	3	49
80	Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. <i>Drugs</i> , 2008 , 68, 1975-2000	12.1	156
79	A 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2008 , 359, 1543-54	59.2	1658
78	Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. <i>Respiratory Medicine</i> , 2008 , 102, 479-87	4.6	75
77	Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. <i>Medical Decision Making</i> , 2008 , 28, 926-37	2.5	20
76	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 91-8	10.2	120
75	High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. <i>Chest</i> , 2008 , 134, 358-367	5.3	149
74	A 56-year-old woman with COPD and multiple pulmonary nodules. <i>Chest</i> , 2008 , 133, 566-9	5.3	7
73	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1676-84		82
72	Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1641-7	2.4	52

71	Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 994-1000	10.2	62
70	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1026-34	10.2	343
69	Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. <i>American Journal of Medicine</i> , 2007 , 120, 435-41	2.4	26
68	Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. <i>American Journal of Medicine</i> , 2007 , 120, S4-13	2.4	16
67	Cyclophosphamide versus placebo in scleroderma lung disease. <i>New England Journal of Medicine</i> , 2006 , 354, 2655-66	59.2	1125
66	Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1829-34 ⁴		156
65	Small airways response to naturalistic cat allergen exposure in subjects with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006 , 118, 1075-81	11.5	44
64	The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. <i>American Journal of Medicine</i> , 2006 , 119, 63-72	2.4	18
63	Cannabis withdrawal among non-treatment-seeking adult cannabis users. <i>American Journal on Addictions</i> , 2006 , 15, 8-14	3.7	102
62	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. <i>Quality of Life Research</i> , 2006 , 15, 1383-94	3.7	24
61	Current Management of Chronic Obstructive Pulmonary Disease. <i>Clinical Pulmonary Medicine</i> , 2005 , 12, S2-S6	0.3	
60	Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?. <i>Current Opinion in Pulmonary Medicine</i> , 2005 , 11, 121-8	3	22
59	Loss of bone density with inhaled triamcinolone in Lung Health Study II. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 1302-9	10.2	78
58	Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. <i>Chest</i> , 2004 , 126, 1123-33	5.3	37
57	Evidence implicating cocaine as a possible risk factor for HIV infection. <i>Journal of Neuroimmunology</i> , 2004 , 147, 26-7	3.5	14
56	Mechanisms for impaired effector function in alveolar macrophages from marijuana and cocaine smokers. <i>Journal of Neuroimmunology</i> , 2004 , 147, 82-6	3.5	44
55	Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2004 , 1, 303-12	2	133
54	The role of long-acting bronchodilators in the management of stable COPD. <i>Chest</i> , 2004 , 125, 249-59	5.3	156

53	Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. <i>Chest</i> , 2003 , 123, 1441-9	5.3	132
52	Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. <i>Chest</i> , 2003 , 124, 57-62	5.3	19
51	Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003 , 284, L298-306	5.8	58
50	Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. <i>Journal of Infectious Diseases</i> , 2003 , 187, 700-4	7	62
49	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. <i>Journal of Neuroimmunology</i> , 2002 , 133, 124-31	3.5	179
48	Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. <i>Chemistry and Physics of Lipids</i> , 2002 , 121, 229-39	3.7	71
47	Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. <i>Journal of Infectious Diseases</i> , 2002 , 185, 701-5	7	86
46	Respiratory and immunologic consequences of marijuana smoking. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 715-815	2.9	121
45	The role of small airway inflammation in asthma. <i>Allergy and Asthma Proceedings</i> , 2002 , 23, 233-42	2.6	32
44	Gender bias in the diagnosis of COPD. <i>Chest</i> , 2001 , 119, 1691-5	5.3	249
43	Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001 , 24, 339-44	5.7	76
42	Effects of Smoked Marijuana on the Lung and Its Immune Defenses. <i>Journal of Cannabis Therapeutics</i> , 2001 , 1, 87-102		1
41	Airway effects of marijuana, cocaine, and other inhaled illicit agents. <i>Current Opinion in Pulmonary Medicine</i> , 2001 , 7, 43-61	3	88
40	Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. <i>Journal of Immunology</i> , 2000 , 165, 373-80	5.3	187
39	Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999 , 20, 1286-93	5.7	109
38	Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. <i>Journal of Neuroimmunology</i> , 1998 , 83, 133-8	3.5	86
37	Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1198-205	9.7	165
36	Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. <i>Respiration</i> , 1998 , 65, 354-62	3.7	70

35	Effects of Crack Cocaine on pulmonary alveolar permeability. <i>Chest</i> , 1997 , 112, 327-35	5.3	20
34	Impact of habitual cocaine smoking on the physiologic response to maximum exercise. <i>Chest</i> , 1997 , 112, 1008-16	5.3	13
33	Acute effects of intravenous cocaine on pulmonary artery pressure and cardiac index in habitual crack smokers. <i>Chest</i> , 1997 , 111, 30-5	5.3	25
32	Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine. A potential etiology for pulmonary injury. <i>Chest</i> , 1997 , 111, 698-705	5.3	45
31	Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. <i>Chest</i> , 1997 , 112, 319-26	5.3	176
30	Acute effects of inhaled and i.v. cocaine on airway dynamics. <i>Chest</i> , 1996 , 110, 904-10	5.3	44
29	Results of a multicenter study of nebulized inhalant bronchodilator solutions. <i>American Journal of Medicine</i> , 1996 , 100, 62S-69	2.4	18
28	Pulmonary status of habitual cocaine smokers. <i>The American Review of Respiratory Disease</i> , 1992 , 145, 92-100		94
27	Effects of smoked marijuana of varying potency on ventilatory drive and metabolic rate. <i>The American Review of Respiratory Disease</i> , 1992 , 146, 716-21		10
26	The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. <i>The American Review of Respiratory Disease</i> , 1992 , 145, 301-10		228
25	Smoked cocaine: patterns of use and pulmonary consequences. <i>Journal of Psychoactive Drugs</i> , 1992 , 24, 265-72	3.6	13
24	Respiratory effects of cocaine freebasing among habitual cocaine users. <i>Journal of Addictive Diseases</i> , 1992 , 11, 59-70	1.7	13
23	Marijuana exposure and pulmonary alterations in primates. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 637-42	3.9	27
22	Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and delta-9-THC. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 651-6	3.9	37
21	Marijuana smoking, pulmonary function, and lung macrophage oxidant release. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 663-9	3.9	31
20	Antimicrobial and respiratory burst characteristics of pulmonary alveolar macrophages recovered from smokers of marijuana alone, smokers of tobacco alone, smokers of marijuana and tobacco, and nonsmokers. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 1351-6		51
19	Relative sensitivity and specificity of salivary and serum cotinine in identifying tobacco-smoking status of self-reported nonsmokers and smokers of tobacco and/or marijuana. <i>Archives of Environmental Health</i> , 1989 , 44, 53-8		51
18	Pulmonary hazards of smoking marijuana as compared with tobacco. <i>New England Journal of Medicine</i> , 1988 , 318, 347-51	59.2	375

17	Acute and chronic effects of marijuana smoking compared with tobacco smoking on blood carboxyhemoglobin levels. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 27-31	3.6	3
16	Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 33-42	3.6	29
15	Chemotaxis of peripheral blood and lung leukocytes obtained from tobacco and marijuana smokers. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 15-20	3.6	6
14	Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 9-14	3.6	19
13	Influence of marijuana potency and amount of cigarette consumed on marijuana smoking pattern. <i>Journal of Psychoactive Drugs</i> , 1988 , 20, 43-6	3.6	17
12	Human and rabbit newborn lung macrophages have reduced anti-Candida activity. <i>Pediatric Research</i> , 1988 , 24, 285-90	3.2	31
11	Tracheobronchial changes in habitual, heavy smokers of marijuana with and without tobacco. <i>The American Review of Respiratory Disease</i> , 1987 , 136, 142-9		90
10	Respiratory effects of cocaine "freebasing" among habitual users of marijuana with or without tobacco. <i>Chest</i> , 1987 , 92, 638-44	5.3	54
9	Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. <i>The American Review of Respiratory Disease</i> , 1987 , 135, 1271-5		70
8	Acute and subacute bronchial effects of oral cannabinoids. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 26-32	6.1	22
7	Small airways function in nonsmokers with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1218-26		29
6	Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 127-33	2.9	9
5	Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 32, 566-71	6.1	94
4	Respiratory status of seventy-four habitual marijuana smokers. <i>Chest</i> , 1980 , 78, 699-706	5.3	67
3	Small airways in progressive systemic sclerosis (PSS). <i>American Journal of Medicine</i> , 1979 , 66, 201-9	2.4	50
2	Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. <i>New England Journal of Medicine</i> , 1976 , 294, 125-9	59.2	90
1	Acute pulmonary physiologic effects of smoked marijuana and oral (Delta)9 -tetrahydrocannabinol in healthy young men. <i>New England Journal of Medicine</i> , 1973 , 289, 336-41	59.2	122